findmyKOL
Clinical trialNCT00003062CompletedPhase 2Interventional

Temozolomide in Patients With Progressive or Recurrent Non-small Cell Lung Cancer

SponsorEuropean Organisation for Research and Treatment of Cancer - EORTCEnrollment70Lung Cancer
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Italy
  • Istituto Nazionale Per la Ricerca Sul Cancro

    Genoa, Italy

Netherlands
  • Vrije Universiteit Medisch Centrum

    Amsterdam, Netherlands

Poland
  • Medical University of Gdansk

    Gdansk, Poland

South Africa
  • Medical Oncology Centre of Rosebank

    Johannesburg, South Africa

United Kingdom
  • Western General Hospital

    Edinburgh, Scotland, United Kingdom

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Jul 1997
Primary completion
31 Jan 2002
Completion
Last update posted
2 Jul 2012
Registered enrollment
70
Registry id
NCT00003062

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.